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ABSTRACT
Questions
• In patients with inoperable locally advanced or
metastatic soft tissue sarcoma, does first-line dose-
intensive chemotherapy supported by growth fac-
tor or autologous bone marrow or stem-cell trans-
plantation improve response rate, time to disease
progression, or survival as compared with standard-
dose chemotherapy?
• What are the effects of first-line dose-intensive
chemotherapy supported by growth factor or au-
tologous bone marrow or stem-cell transplantation
on toxicity and quality of life?
Perspectives
Because therapeutic options for adult patients with ad-
vanced or metastatic soft tissue sarcoma are scarce
and the possibility of cure for these patients is ex-
tremely limited, the Sarcoma Disease Site Group (DSG)
felt that a review of the available literature on dose-
intensive chemotherapy for adult patients with locally
advanced or metastatic soft tissue sarcoma and subse-
quent development of a clinical practice guideline
based on the evidence were important.
Methodology
A systematic review was developed and clinical rec-
ommendations relevant to patients in Ontario were
drafted. The practice guideline report was reviewed and
approved by the Sarcoma DSG, which comprises medi-
cal oncologists, radiation oncologists, surgeons, a
pathologist, a methodologist, and community representa-
tives. External review by Ontario practitioners was ob-
tained through a mailed survey, the results of which were
incorporated into the practice guideline. Final review
and approval of the practice guideline was obtained from
the Report Approval Panel.
Practice Guideline
Based on the systematic review, consensus, and external
review, the Sarcoma DSG makes these recommendations:
• Dose-intensive chemotherapy with growth factor
support is not recommended in the first-line treat-
ment of patients with inoperable locally advanced
or metastatic soft tissue sarcoma.
• The data are insufficient to support the use of high-
dose chemotherapy with autologous bone marrow
or stem-cell transplantation as first-line treatment
in this group of patients.
• Eligible patients should be encouraged to enter clini-
cal trials assessing novel approaches or compounds.
Qualifying Statements
High-dose chemotherapy with growth factor or autolo-
gous bone marrow or stem-cell transplantation has ad-
verse effects similar to those seen with standard-dose
chemotherapy. With high-dose regimens, the incidence
of grades 3 and 4 thrombocytopenia is significantly high-
er, and neutropenic fever and febrile neutropenia occur
more frequently. Compared with standard treatment, the
rate of treatment-related death is also higher with high-
dose regimens.
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1. QUESTION
• In patients with inoperable locally advanced or
metastatic soft tissue sarcoma, does first-line dose-
intensive chemotherapy supported by growth fac-
tor or autologous bone marrow or stem-cell trans-
plantation improve response rate, time to disease
progression, or survival as compared with standard-
dose chemotherapy?
• What are the effects of first-line dose-intensive
chemotherapy supported by growth factor or au-
tologous bone marrow or stem-cell transplantation
on toxicity and quality of life?
For the purposes of this practice guideline, “dose-
intensive chemotherapy” is defined as regimens ad-
ministered with intent to increase standard doses of
chemotherapy with the support provided by the use of
either, or both of, hematopoietic growth factors or autolo-
gous bone marrow or stem-cell transplantation. “Stand-
ard chemotherapy” includes regimens that were previ-
ously evaluated in a large phase II trial or a randomized
phase III trial without growth factor support.
2. CHOICE OF TOPIC AND RATIONALE
Treatment of advanced (unresectable or metastatic) soft
tissue sarcoma remains a challenging and problematic
area in oncology. Most people who present with meta-
static disease are not candidates for surgical resection,
and consequently, systemic therapy is the only remaining
option 1,2. Cytotoxic agents such as doxorubicin and
ifosfamide are commonly used and have demonstrated
activity in patients with metastatic soft tissue sarcoma.
Studies showed that approximately 20%–30% of patients
respond to those drugs used as single agents 3–6. In addi-
tion, a number of prospective trials demonstrated that
growth factors such as granulocyte colony–stimulating
factor (G-CSF) and granulocyte–macrophage colony–
stimulating factor (GM-CSF), or autologous bone marrow
or stem-cell transplantation may improve hematologic
tolerance for dose-intensive combination chemothera-
py regimens 7–9.
Because therapeutic options for adult patients with
advanced or metastatic soft tissue sarcoma are extreme-
ly limited and the possibility of cure for these patients
is nearly nonexistent, the Sarcoma Disease Site Group
(DSG) felt that a review of the available literature on
dose-intensive chemotherapy for adult patients with
locally advanced or metastatic soft tissue sarcoma and
subsequent development of a clinical practice guideline
based on the evidence were important.
3. METHODOLOGY
3.1 Guideline Development
The present practice guideline was developed by the
Sarcoma DSG of Cancer Care Ontario’s Program in
Evidence-Based Care (PEBC) using the methods of
the practice guidelines development cycle 10. This
practice guideline is a convenient source of the best
available evidence on dose-intensive chemotherapy
for patients with inoperable locally advanced or meta-
static soft tissue sarcoma. It was developed through
systematic review, evidence synthesis, and input from
practitioners in Ontario. The systematic review (cur-
rently under consideration for publication elsewhere)
forms the basis of this report and was used by the
Sarcoma DSG to formulate draft recommendations
meant to promote evidence-based practice in Ontario.
The PEBC is editorially independent of Cancer Care
Ontario and the Ontario Ministry of Health and Long-
Term Care.
External review was obtained for the practice
guideline report through a mailed survey of Ontario
practitioners. The survey consisted of items address-
ing the quality of the draft practice guideline report
and the recommendations, and asking whether the rec-
ommendations should serve as a practice guideline.
Final approval of the original practice guideline re-
port was obtained from the PEBC Report Approval
Panel. All members of the Sarcoma DSG disclosed
information on potential conflicts of interest. No con-
flicts were declared.
3.2 Literature Search Strategy
A systematic search of the MEDLINE, EMBASE, and
Cochrane Library databases for 1980–2006 was con-
ducted for practice guidelines, systematic reviews
or meta-analyses, and randomized controlled trials,
controlled clinical trials, and phase I, II, and III clini-
cal trials. In addition, the 1998–2005 conference pro-
ceedings of the American Society of Clinical Oncolo-
gy (ASCO) were searched for abstracts of relevant
trials. The Canadian Medical Association Infobase
(mdm.ca/cpgsnew/cpgs/index.asp) and the National
Guidelines Clearinghouse (www.guideline.gov/)
were also searched for existing evidence-based prac-
tice guidelines.
3.3 Results
Two phase III randomized trials 11,12, twelve phase II
trials 7,13–23, and five phase I dose-escalation trials 24–28
met the eligibility criteria and were included in the sys-
tematic review.
In the first randomized trial, patients received ei-
ther a standard dose of doxorubicin and ifosfamide or
a high dose of doxorubicin combined with a standard
dose of ifosfamide 11. That trial did not detect any sta-
tistically significant differences in overall survival or
response rate. The second trial randomized patients to
either standard-dose MAID [mesna, Adriamycin (dox-
orubicin: Pharmacia, Kalamazoo, MI, U.S.A.), ifos-
famide, dacarbazine] or MAID + 25% with G-CSF sup-
port 12. Survival data have not yet been reported forPRACTICE GUIDELINE SERIES
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that trial, and preliminary results suggest no benefit in
response rate. Both randomized trials detected higher
rates of adverse effects in patients receiving the high-
dose regimens.
One randomized phase II trial 16 that examined
the role of high-dose ifosfamide found no statistically
significant improvements in overall or disease-free
survival between the high- and standard-dose
chemotherapy arms. The remaining phase II trials re-
ported promising response rates and overall median
survivals; however, those results were not replicated
in the randomized trials.
4. DSG CONSENSUS PROCESS
The report was circulated for review and discussion
by the Sarcoma DSG, which comprises medical on-
cologists, radiation oncologists, surgeons, a patholo-
gist, a methodologist, and community representatives.
The members conceded that, given the available data,
high-dose chemotherapy with growth factor or autolo-
gous bone marrow or stem-cell transplantation is not
recommended for the routine treatment of patients
with inoperable locally advanced or metastatic soft
tissue sarcoma.
5. INTERNAL REVIEW
The completed report was reviewed and approved by
the PEBC Report Approval Panel, which consists of two
members, including an oncologist with expertise in
clinical and methodology issues. The Panel offered
these comments:
• A recommendation concerning the use of stem cell
transplantation cannot be made given that insuffi-
cient data exist.
• The recommendation did not specify the first-line
treatment setting.
• Should the phase I and phase II trials assessing
growth factors be included, given the availability
of the randomized trials?
To address the key comments, the Sarcoma DSG
• created two separate recommendations, with one
stating that a recommendation for the use of bone
marrow or stem-cell transplantation could not be
made because of insufficient data;
• incorporated “first-line” into the recommendations;
and
• noted that inclusion of phase I and phase II trials
was in part a reflection of past practice and in part
the result of a desire on the part of the DSG to pro-
vide a detailed description of the efficacy and tox-
icity of the treatments.
Once those key issues were addressed, the docu-
ment was approved without further changes.
6. EXTERNAL REVIEW
The Sarcoma DSG circulated the clinical practice guide-
line and systematic review to practitioners in Ontario
for review and feedback.
6.1 Methods
Feedback was obtained through a mailed survey of 74
practitioners in Ontario, including medical oncologists,
radiation oncologists, and surgeons. The survey con-
sisted of items evaluating the methods, results, and
interpretive summary used to inform the draft recom-
mendations and asking whether the draft recommen-
dations should be approved as a practice guideline.
Written comments were invited. The survey was
mailed on February 22, 2006. Follow-up reminders were
sent at 2 weeks (post card) and 4 weeks (complete
package mailed again). The Sarcoma DSG reviewed
the results of the survey.
6.2 Results
Of the 74 practitioners surveyed, 23 responded (31%
response rate). Responses include returned completed
surveys and telephone, fax, and e-mail responses. Of
the practitioners that responded, 8 indicated that the
report was relevant to their clinical practice, and they
completed the survey. One practitioner indicated that
the topic was relevant, but that practitioner did not com-
plete the questionnaire because of a lack of direct in-
teraction with patients. That practitioner’s comments
were therefore not included in the results presented
here. Table I summarizes key results of the practitioner
feedback survey.
6.3 Summary of Written Comments
Of the 8 respondents, 1 clinician provided suggestions
for future document development and content. Those
suggestions were noted at the PEBC office. No other
feedback was provided.
7. PRACTICE GUIDELINE
The present practice guideline reflects the integration
of the draft recommendations with the feedback ob-
tained from the external review process. The guide-
line was approved by the Sarcoma DSG and the Report
Approval Panel.
7.1 Recommendations
• Dose-intensive chemotherapy with growth factor
support is not recommended in the first-line treat-
ment of patients with inoperable locally advanced
or metastatic soft tissue sarcoma.
• The data are insufficient to support the use of high-
dose chemotherapy with autologous bone marrowVERMA et al.
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or stem-cell transplantation as first-line treatment
in this group of patients.
• Eligible patients should be encouraged to enter
clinical trials assessing novel approaches or com-
pounds.
7.2 Qualifying Statements
High-dose chemotherapy with growth factor or autolo-
gous bone marrow or stem-cell transplantation has ad-
verse effects similar to those seen with standard-dose
chemotherapy. With high-dose regimens, the incidence
of grades 3 and 4 thrombocytopenia is significantly
higher, and neutropenic fever and febrile neutropenia
occur more frequently. Compared with standard treat-
ment, the rate of treatment-related death is also higher
with high-dose regimens.
8. PRACTICE GUIDELINE DATE
This clinical practice guideline is based on work com-
pleted in April 2006. All approved PEBC clinical practice
guidelines are reviewed and updated regularly. Please visit
the Cancer Care Ontario Web site (www.cancercare.on.
ca) for a complete list of current projects.
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